Apogee Therapeutics Inc. (APGE)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Apogee Therapeutics, Inc. (APGE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Apogee Therapeutics, Inc. (APGE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcript
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcript
Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing
Apogee Therapeutics, Inc. remains a Buy, driven by zumilokibart's potential in atopic dermatitis and recent positive Phase 2b data. Zumilokibart's efficacy matches leading biologics, with the key differentiator being 2–4 annual doses, pending maintenance data in 2025. The Blackstone collaboration secures up to $1.3B in funding, eliminating near-term dilution risk and supporting commercialization.
Apogee Therapeutics: Targeting Atopic Dermatitis
Apogee Therapeutics, Inc. has roughly doubled since October 2025, driven by promising data for the lead asset zumilokibart in atopic dermatitis. Zumi offers a significant compliance advantage with once-quarterly or twice-annual dosing, outperforming current biologics in efficacy and maintenance. Upcoming catalysts include Part B APEX data in 2Q26 and APG279 combination data in 2H26, with Phase 3 initiation and potential news vacuum thereafter.
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy
Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and infrequent dosing boosting its promise.
Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone
Apogee Therapeutics, Inc. maintains a Strong Buy rating following positive 52-week maintenance data for zumilokibart in moderate-to-severe Atopic Dermatitis [AD]. APGE's half-life extended monoclonal antibody technology enables less frequent dosing, with Q3M and Q6M regimens showing EASI-75 responses of 75% and 85% in Week 16 responders. Upcoming catalysts include 16-week induction data from Part B of the phase 2 APEX trial in Q2 2026 and potential phase 3 initiation in H2 2026.
Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript
Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript
Apogee Therapeutics: Two Shots A Year, One Shot At Disruption
Apogee Therapeutics (APGE) remains a Buy, supported by strong Phase 2 data for zumilokibart in atopic dermatitis (AD) and a robust cash position. Zumilokibart's infrequent dosing (Q3M/Q6M) offers a key compliance advantage, with efficacy and safety comparable to market leaders and manageable side effects. My DCF model values APGE at $73.07/share, reflecting a $5B intrinsic equity value, though current market cap suggests limited near-term upside absent M&A.
Apogee Therapeutics: 2026 Inflection Point In Immunology
Apogee Therapeutics (APGE) leverages IL-13 pathway optimization to enable less frequent dosing, targeting a leadership shift in biologic treatment for inflammatory diseases. APGE's $913 million cash position provides operational runway into 2028, supporting pivotal Phase II/III trials without near-term dilution risk. Zumilokibart's extended half-life and clean safety profile position APGE to challenge Dupixent, with physician surveys indicating strong preference for reduced dosing frequency.
Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript
Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript
Apogee Therapeutics, Inc. (APGE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Apogee Therapeutics, Inc. (APGE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year?
Here is how Apogee Therapeutics Inc. (APGE) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
